Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders
22 nov. 2022 07h00 HE
|
Khondrion
Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders Sonlicromanol for MELAS spectrum disorders – a rare, progressive primary...
Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders
22 nov. 2022 02h00 HE
|
Khondrion
Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders Sonlicromanol for MELAS spectrum disorders – a rare, progressive primary...
Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders
10 janv. 2022 02h00 HE
|
Khondrion
Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a...
Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases
21 avr. 2021 07h00 HE
|
Khondrion
Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases Study will examine the pharmacokinetics, safety and efficacy of...
Khondrion receives EMA agreement on its Paediatric Investigation Plan for sonlicromanol
18 janv. 2021 02h00 HE
|
Khondrion
Khondrion receives EMA agreement on its Paediatric Investigation Plan for sonlicromanol NIJMEGEN, the Netherlands – 18 January, 2021: Khondrion, a clinical-stage biopharmaceutical company...
Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA
28 sept. 2020 07h00 HE
|
Khondrion
Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA Designation granted for the treatment of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like...
Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA
28 sept. 2020 02h00 HE
|
Khondrion
Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA Designation granted for the treatment of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like...
Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential treatment pathway with sonlicromanol
15 avr. 2020 03h00 HE
|
Khondrion
Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential treatment pathway with sonlicromanol Elevated levels of PGE2 known to...
Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases
27 janv. 2020 03h00 HE
|
Khondrion
Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases Study will examine impact on cognitive function from one of the most advanced disease-modifying...